> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-41/
- Published: 2021-05-31T12:00:00.000Z
- Updated: 2026-09-14T17:01:06.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149239

Drug Product Communications Info Collection5/28/2021 *Federal Register* notice: FDA has announced that an information collection entitled ‘‘Data to Support Drug Product Communications’’ has been approved by OMB. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-04-30/pdf/2021-09043.pdf?ref=fdaweb.com).

Updated List of Device Consensus Standards5/28/2021 *Federal Register* notice: FDA is announcing a publication containing modifications to its list of standards FDA recognizes for use in premarket reviews. The publication, *Modifications to the List of Recognized Standards, Recognition List Number: 055*, is intended to assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-04-29/pdf/2021-08992.pdf?ref=fdaweb.com).

Info Collection on Drug Compounding5/27/2021 *Federal Register* notice: FDA is seeking comments on an information collection revision entitled “Human Drug Compounding, Repackaging, and Related Activities Regarding Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act” (OMB Control Number 0910-0858). The collection supports implementation of sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which govern compounding by pharmacies, outsourcing facilities, and other entities. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-04-29/pdf/2021-08943.pdf?ref=fdaweb.com).

Data Monitoring Committee Info Collection5/26/2021 *Federal Register* notice: FDA is seeking comments on an information collection extension entitled “Establishment and Operation of Clinical Trial Data Monitoring Committees” (OMB Control Number 0910-0581). The collection supports agency regulations and associated agency guidance requiring sponsors to monitor studies evaluating new drugs, biologics, and devices. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-04-29/pdf/2021-08963.pdf?ref=fdaweb.com).